Disease progression and recurrence are major barriers to survival for breast cancer patients. Understanding the etiology of recurrent or metastatic breast cancer and underlying mechanisms is critical for the development of new treatments and improved survival. Here, we report that two commonly overexpressed breast cancer oncogenes, Ron (Recepteur d'Origine Nantaise) and DEK, cooperate to promote advanced disease through multipronged effects on β-catenin signaling. The Ron receptor is commonly activated in breast cancers, and Ron overexpression in human disease stimulates β-catenin nuclear translocation and is an independent predictor of metastatic dissemination. Dek is a chromatin-associated oncogene whose expression has been linked to cancer through multiple mechanisms, including β-catenin activity. We demonstrate here that Dek is a downstream target of Ron receptor activation in murine and human models. The absence of Dek in the MMTV-Ron mouse model led to a significant delay in tumor development, characterized by decreased cell proliferation, diminished metastasis and fewer cells expressing mammary cancer stem cell markers. Dek complementation of cell lines established from this model was sufficient to promote cellular growth and invasion. Mechanistically, Dek expression stimulated the production and secretion of Wnt ligands to sustain an autocrine/ paracrine canonical β-catenin signaling loop. Finally, we show that Dek overexpression promotes tumorigenic phenotypes in immortalized human mammary epithelial MCF10A cells and, in the context of Ron receptor activation, correlates with disease recurrence and metastasis in patients. Overall, our studies demonstrate that DEK overexpression, due in part to Ron receptor activation, drives breast cancer progression through the induction of Wnt/β-catenin signaling.
INTRODUCTION
Despite high survival rates for early-stage breast cancer, it is still the second leading cause of cancer-related deaths in the United States. This is because of the poor survival associated with latestage, invasive disease and treatment-resistant breast cancers. Most new diagnoses are invasive cancers, which have poor survival rates. 1 Therefore, it is important to identify proteins that predict disease relapse or progression and that may also be therapeutic targets.
Several reports identified the Ron (Recepteur d'Origine Nantaise) receptor tyrosine kinase, a MET family member, as an important driver of breast tumorigenesis. Ron is minimally expressed in normal breast epithelium, but is highly expressed in approximately 50% of human breast cancers. 2 Ron activation from overexpression has been implicated in driving metastasis and correlates with poor prognosis. 2, 3 Little is known about the molecular mechanisms through which Ron promotes breast cancer proliferation and metastases. Recently, it was reported that Ron activation leads to c-abl activation and proliferating cell nuclear antigen (PCNA) localization to chromatin to drive proliferation. 4 Ron also activates numerous cytoplasmic signaling pathways, including Ras/MAPK, PI3K and β-catenin through direct phosphorylation, and regulates many downstream targets.
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Here, we identify a novel nuclear effector of Ron activation, the DEK oncogene. DEK is a unique protein with no known paralogs or enzymatic function. 8 It is predominantly chromatin bound and has been implicated in numerous processes including DNA repair, replication, transcriptional regulation and mRNA splicing. [8] [9] [10] [11] [12] [13] [14] The role of DEK in these processes is unclear, but may be due to its histone chaperone and Su(var) activities that regulate chromatin organization. 15, 16 Many reports have shown that DEK can function as a cofactor for transcriptional regulation; however, DEK can both repress and activate transcription of target genes. For example, several reports have shown that DEK inhibits NF-κB/p65/RelA transcriptional activity, [17] [18] [19] decreases hTERT expression in leukemias 20 and can interact with poly (ADP-ribose) polymerase 1 (PARP1) to restrict the accessibility of the transcription complexes to chromatin. 21 Other reports indicate that DEK can also activate transcription by interacting with several transcription factors, including C/EBPα during myeloid differentiation, 22 nuclear ecdysone receptor in Drosophila 16 and AP-2α in rat liver and human cell lines. 10 Interestingly, DEK can also be secreted and is an autoantigen in patients with juvenile idiopathic arthritis and was detected in the urine of patients with bladder cancer. [23] [24] [25] Macrophages can secrete DEK and neighboring cells can internalize it in a heparan sulfate-dependent process where it then completes its normal nuclear functions. 26 DEK is transcriptionally upregulated in several solid tumors and was initially discovered as a CAN (NUP214) fusion gene in acute myeloid leukemia. [27] [28] [29] [30] [31] [32] Transcriptional upregulation is accomplished via the Rb/E2F pathway and steroid hormone signaling, but 6p22.3 amplifications have been noted. [32] [33] [34] [35] [36] Cell culture, murine chemical carcinogenesis and xenograft tumor models indicate that DEK overexpression promotes proliferation. 29, 30, 32, 37 There are several possible molecular mechanisms for this DEKmediated proliferation, including upregulation of ΔNp63α and, in the case of the DEK-NUP214 fusion, mTORC1 activity. 29, 30, 37, 38 Additional cell culture models implicate DEK in promoting cell invasion, in part due to β-catenin signaling. 29, 32 However, the oncogenic functions of DEK have not been tested in vivo using genetically engineered mouse models. Furthermore, the molecular mechanisms through which full-length DEK drives proliferation and β-catenin signaling in breast cancer are unknown.
Here, we crossed Dek −/− mice with the MMTV-Ron murine breast cancer model to determine the requirement for Dek during breast cancer initiation and progression. We report that Dek is a downstream target of activated Ron signaling such that the MMTV-Ron model recapitulates DEK overexpression observed in some human breast cancers. The loss of Dek delayed tumor growth and decreased lung metastases. We generated Dek-proficient and -deficient breast cancer cell lines from the murine tumors and found that reconstitution of Dek in knockout cells rescued cellular growth and invasive phenotypes in vitro. Importantly, we present new evidence that Dek-expressing cells can drive the proliferation of cells within the microenvironment through stimulated expression and secretion of Wnt4, Wnt7b and Wnt10b. Finally, we translate the observed oncogenic DEK activities, and the combination of Ron and DEK activation, to human breast cancer using three-dimensional (3D) cell culture models, tissue microarrays and patient survival data. We propose that DEK drives tumor growth and progression, particularly in the context of Ron receptor activation, via Wnt ligand production and subsequent activation of the β-catenin pathway.
RESULTS
The MMTV-Ron mouse model recapitulates DEK overexpression observed in breast cancer The MMTV-Ron mouse is an established malignant breast cancer model wherein Ron expression is controlled by the MMTV mammary-specific promoter. Mice begin to develop tumors at 4-5 months of age with a high prevalence of lung metastases. isolated from an MMTV-Ron tumor were treated with the Ron ligand, hepatocyte growth factor-like protein (HGFL; Supplementary Figure S1 ). 3, 39 Ron activation with HGFL resulted in increased Dek mRNA and protein (Figures 1c and d (Figure 2a ). There were no significant differences in tumor incidence or in the number of tumors that eventually developed (Figure 2a and data not shown). We previously published that DEK depletion by short hairpin RNA (shRNA) in MDA-MB-468 human breast cancer cells results in smaller xenograft tumors associated with decreased tumor proliferation. 29 To determine if decreased proliferation accounted for the delayed tumor onset in Ron tg Dek −/− mammary glands, preneoplastic glands were analyzed for bromodeoxyuridine (BrdU) incorporation as a proliferation marker. Glands from Ron tg Dek −/− mice had substantially fewer BrdU-positive cells when compared with control mice (Figure 2b ). To assess directly the necessity of Dek for tumor cell growth, cell lines were established from tumors isolated from independent mice. Dek expression was subsequently decreased by shRNA (Deksh) in Ron tg Dek +/+ -derived tumors, and murine Dek (mDek) was exogenously expressed in cell lines generated from Ron tg Dek −/− tumors (see western blot analysis depicted as insets in Figure 2c) . Figure S2A) . Interestingly, there also was a trend toward diminished tumor formation when cells derived from Ron tg Dek −/− tumors were injected into the mammary fat pad (Supplementary Figure S2B) . Taken together, the data indicate that Dek contributes to tumor initiation and growth in the transgenic mouse model through enhanced proliferation and promotes BCSC phenotypes.
Dek expression promotes cancer metastasis in vivo and in vitro Previous reports using in vitro transwell assays suggest that DEK conferred invasive potential to breast cancer cells via a β-catenindependent mechanism. 29 (Figure 3a) . Lung metastases were positive for cytokeratin 5 staining, indicating they were epithelial in origin (Supplementary Figure S3A) . One potential mechanism of metastasis is through the expression of matrix metalloproteases (MMPs), including the Wnt targets MMP2 and MMP9. 43 Dek drives proliferation through Wnt signaling We previously showed that DEK expression correlated with β-catenin activity in human breast cancer cell lines and that this activity drove cell invasion in Matrigel transwell assays. 29 However, the mechanism for this regulation was unknown. Preliminary data from a quantitative reverse transcription-PCR array was used, wherein we screened for expression differences of over 80 Wnt signaling pathway members in Dek +/+ versus Dek −/− mouse embryonic fibroblasts (MEF) 13 to select relevant Wnt/β-catenin pathway members for further analysis (Supplementary Figures S4A  and B) . We identified Wnt4, Wnt7b and Wnt10b to be differentially regulated by Dek expression (Figure 4a ). Deksh in R7 cells resulted in decreased Wnt expression, whereas complementation of four Ron tg Dek −/− cell lines with mDek resulted in increased Wnt expression. Wnt10b, a canonical Wnt ligand, was pursued owing to its strong association with breast cancer development and proliferation. 44, 45 The observed differences in Wnt10b mRNA correlated with differences in secreted protein levels detected in conditioned media (Figure 4b ). The upregulation of Wnts also correlated with increased β-catenin transcriptional activity as determined by the TOP/FOP luciferase reporter assay (Figure 4c ), a finding that agrees with our previous work with MEFs. 29 We also observed upregulation of the pro-proliferative Wnt/β-catenin target gene cyclin D1 and increased protein levels of other Wnt pathway members ( Figure 4d and Supplementary Figure S4C Figure 5C ). Taken together, this suggests that Dek-mediated tumor growth is associated with Wnt expression and subsequent β-catenin activation.
Ron receptor activation increases DEK expression and DEK overexpression confers tumorigenic phenotypes to immortalized human MECs We treated T47D cells with HGFL to determine if Ron activation also upregulates DEK in human breast cancer cell lines. DEK mRNA was upregulated within hours of HGFL stimulation, resulting in elevated protein levels (Figures 6a and b) . This further supports the hypothesis that DEK overexpression in breast cancer cell lines is induced by Ron receptor activation.
To determine if DEK overexpression promoted tumorigenic phenotypes in human mammary cells similar to that observed in the mouse, we used 3D cultures of MCF10A immortalized human MECs transduced with control R780 vector or R780:DEK. 29 This 3D human cell culture model closely mimics the structure of the mammary gland, with a spherical layer of polarized epithelium and a hollow lumen. 46 DEK overexpression resulted in a hyperplastic phenotype, as evident by the enlarged acinar structures and filled lumens (Figure 6c , top and center panels). Wnt signaling is known to regulate cell and tissue polarity. [47] [48] [49] Therefore, we assessed polarity in this 3D context by staining for the apical surface marker, GM130. DEK-overexpressing acini contained more cells with deregulated polarity, as indicated by aberrant localization of GM130 (Figure 6c , top panel, white arrows and graph below). When the acini were cultured in a mix of Matrigel and collagen to promote invasive phenotypes, DEK overexpression led to the production of invasive laminin-V-negative multicellular structures, which were not observed in control cells (Figure 6c , bottom panel and data not shown).
Ron and DEK expression cooperate to promote β-catenin activity and disease progression in human primary breast cancers Immunohistochemical staining of serial sections from two breast cancer microarrays was performed. Analyses were limited to infiltrating ductal carcinomas, and we determined that 54% (15 of 28) of samples expressed high levels of DEK, whereas 46% (13 of 28) highly expressed Ron. By themselves, the expression of each protein was suggestive of high β-catenin levels, indicating pathway activation (Supplementary Figure S5A) . When combined, 74% (31 of 42) of breast cancers expressed high levels of Ron and/ or DEK, which also was highly predictive of strong β-catenin staining (Figure 6d) .
Finally, an in silico meta-analysis of patient and gene expression data archived in Kaplan-Meier Plotter (http://www.kmplot.com) was performed to assess the impact of DEK and Ron expression on patient survival. In each case, high Dek expression was very predictive of poor patient outcome and the strength of the association was enhanced by adding Ron expression ( Supplementary Figures S5B and D) . Taken together, high DEK and Ron expression were predictive of early relapse in breast cancer patients that did not receive systemic endocrine therapy or chemotherapy (Figure 6e ). The combined markers also correlated with a higher risk for developing distant metastases in breast cancer patients treated with systemic therapies (Figure 6f ) and with poor postprogression survival in all patients (Supplementary Figure S5D) .
Our results lead to a proposed model whereby elevated DEK expression results in the enhanced transcription and secretion of Wnt ligands that can promote cellular proliferation through a paracrine mechanism that is driven by β-catenin signaling ( Figure 7) . Furthermore, Ron receptor tyrosine kinase activation is a novel mechanism for DEK upregulation and, independently, can promote β-catenin stabilization and subsequent transcriptional activity (Figure 7) . 6 This combination of events converging upon the β-catenin pathway can then contribute to tumor growth and metastasis.
DISCUSSION
We previously published that Dek −/− mice developed fewer papillomas and were delayed in papilloma formation in a chemically induced model of skin cancer. 30 We provide the first report of the role of the DEK oncogene in a genetic murine model of malignant breast cancer. In this report, the absence of DEK did not prevent tumor formation and the mice ultimately developed similar numbers of tumors. However, Dek −/− mice show delayed tumor initiation and have significantly fewer proliferating cells in preneoplastic mammary glands. This is supported by the finding that proliferation could be rescued by exogenous Dek expression in independently generated cell lines from these Dek − / − tumors. Importantly, we also have observed the relationship between Dek expression and cell growth in an esophageal cancer cell line derived from a murine 4NQO chemical carcinogenesis model, indicating that this correlation is not limited to the MMTV-Ron model (Supplementary Figure S6A) . 37 In human cancers, RNA interference-mediated DEK loss has been reported to cause apoptosis or senescence, as well as decreased proliferation in the surviving cells. 29, 32, 34, 35, 50 Factors that determine the cellular response to DEK depletion are poorly understood, although p53, MCL-1 and p65 functionality have been implicated. 18, 27, 50 The fact that Dek-knockout mice are viable seems to be at odds with the findings in human cells. However, differentiated human keratinocytes are largely resistant to apoptosis and senescence after DEK depletion by shRNA expression. This suggests that the differentiated, largely quiescent tissues in the mouse may not be markedlly affected by the loss of Dek under controlled stress and pathogen-free conditions. It is of interest that MEFs from Dek − / − mice are slightly less proliferative with elevated numbers of senescent cells under normal culture conditions compared with Dek +/+ MEFs, possibly because of increased baseline levels of DNA damage. However, knockout MEFs are significantly more senescent and apoptotic when stressed, such as treatment with etoposide. 13 Therefore, we hypothesize that Dek/DEK expression promotes proliferation through Wnt signaling and ΔNp63 levels; however, the loss of Dek causes decreased mitogenic signaling as well as DNA damage, which, when exacerbated by environmental stress and/ or genetic background, leads to a marked apoptotic or senescent response. Molecular mechanism(s) through which DEK promotes proliferation are not well understood. Cell-free assays and immunoprecipitation experiments suggest that DEK may facilitate DNA replication.
9,14 DEK also promotes proliferation through ΔNp63 protein activities, but the effectors of this pathway remain unexplored. 29, 51, 52 Our previous studies have shown that DEK expression correlates with proliferation by BrdU incorporation in xenograft tumors and organotypic raft cultures of the skin, but the molecular drivers behind this finding were not identified. 29, 52 We also published previously that DEK expression correlates with β-catenin activity in human breast cancer 29 and we have observed this correlation in primary cells from human head and neck squamous cell carcinomas (Supplementary Figures S6B and C) , thus supporting broad importance for the observed DEK-β-catenin signaling axis in solid tumors. Here, we connect our previous findings and identify a molecular mechanism through which DEK can promote proliferation and β-catenin activitythrough the transcriptional regulation of Wnt4, Wnt7b and Wnt10b. These three Wnts have been implicated in promoting oncogenic phenotypes and proliferation. In particular, Wnt10b is a known canonical Wnt ligand that prompts the stabilization and activation of β-catenin and can promote proliferation in triplenegative breast cancer. 53 Wnt10b is an early marker of the mammary lineage, a crucial driver of mammary gland development, and supports mammary stem cell proliferation as suggested by regulation of mammary stem cell marker Sca-1. 44, 54, 55 Wnt10b also is overexpressed in breast cancer cell lines and can induce transformation; furthermore, MMTV-Wnt10b mice develop hyperplasia and excessive ductal branching, phenotypes that precede the development of adenocarcinomas. [44] [45] [46] Wnt4 expression also supports basal mammary epithelial stem cell proliferation, promotes mammary gland development and branching during pregnancy, and is overexpressed in breast cancer cell lines, although it is not transforming by itself. [56] [57] [58] Wnt7b is a noncanonical ligand whose upregulation has been observed in other murine breast cancer models and was shown to promote epithelial proliferation in the lung. [59] [60] [61] [62] [63] All three of these Wnts are known to be expressed in human breast tissue and were reported to be overexpressed in breast cancer. 64 Additional work will be required to determine whether Dek-mediated transcription of Wnt ligands is due to the role of DEK in chromatin reorganization or as a transcriptional cofactor. 15, 16 Furthermore, we report DEK-mediated positive regulation of β-catenin in both breast cancer and head and neck squamous cell carcinomas, which suggests that this oncogenic mechanism may be relevant for several types of solid tumors.
In coculturing experiments, we found that Dek-expressing cells could promote the proliferation of neighboring Dek-deficient cells through a paracrine signaling mechanism. Importantly, inhibiting the secretion of Wnt ligands with the Porcupine inhibitor, IWP-2, markedly reduced this pro-proliferative effect. This suggests that Dek-expressing cells promote the proliferation of cells within the tumor microenvironment. It is also noteworthy that IWP-2 did not entirely eliminate the pro-proliferative effect observed in coculture experiments, indicating that Dek-expressing cells may be secreting other growth factors that drive the proliferation of neighboring cells. Interestingly, this may explain why DEK is not expressed in every cell in primary invasive breast adenocarcinomas; only a fraction of the cells may need to express DEK to drive proliferation of the entire tumor. 29 In addition, Wnt10b and Wnt4 drive mammary stem cell proliferation and Wnt/β-catenin activity is a well-known regulator of the normal and cancer stem cell populations. Future studies will determine if the positive effect of Dek expression on the size of the mouse and human breast cancer stem cell population is due to Wnt expression and β-catenin activation driving cancer stem cell proliferation.
This report highlights for the first time a role of Dek expression in an in vivo model of cancer metastasis. Although Dek loss did not prevent metastases, it significantly decreased metastatic tumor burden in the lungs and resulted in reduced liver metastases. We saw no correlation between Dek expression and the expression of Wnt target genes MMP2 and MMP9; however, this does not exclude other potential mechanisms. A possible alternative is that Dek may also regulate the expression of non-canonical Wnt ligands, such as Wnt5a and Wnt7b, which can activate the Rho/ Rac planar cell polarity pathway to direct cell motility. 65, 66 Interestingly, DEK loss was recently shown to regulate negatively Rho signaling in non-small-cell lung cancer. 67 In addition to lung metastases, we observed that Dek expression significantly promoted invasion in transwell assays in multiple murine breast cancer cell lines and in primary head and neck squamous cell carcinoma cells (Supplementary Figure S6D) , which agrees with previous reports in human breast and lung cancer and indicates that DEK-mediated invasion is relevant to several cancer types. 29, 32 Of interest, breast patient data associated high DEK expression with an increased risk for distant metastasis in previously nodenegative patients. The overall finding is that while Dek is not required for metastasis, it promotes cellular invasion and the growth of metastatic tumors. Interestingly, Wnt signaling has also been implicated in cellular motility and cancer metastasis. In canine breast adenocarcinomas, Wnt7b was found to be upregulated in metastatic cell lines isolated from the lungs compared with isogenic primary tumor cell lines. 68 Wnt10b and Wnt4 are potent regulators of mammary gland branching, which leads us to hypothesize that they may be involved in DEKmediated promotion of cancer cell motility when overexpressed in tumors. 44, 58 We have already reported that DEK knockdown decreased invasion in vitro in human breast cancer cells, and invasion was rescued by the expression of a constitutively active β-catenin construct. 29 This report, combined with our previous work, suggests that DEK-mediated activation of Wnt/β-catenin signaling, at least in part, promotes proliferation, invasion and altered cell polarity.
Finally, we show that elevated DEK expression, partially due to Ron activation, is relevant to human breast cancer. Exogenous expression of DEK in immortalized MCF10A cells grown in 3D culture induces tumorigenic phenotypes reminiscent of invasive adenocarcinomas. Furthermore, DEK expression can be induced by Ron receptor activation with HGFL. This combination of Ron and DEK expression are highly predictive of strong β-catenin staining by immunohistochemistry, disease relapse in patients not treated with systemic therapies and distant metastases in patients who have received systemic therapies. This indicates that Ron and DEK cooperate to promote breast cancer in mice and humans. Although the signaling events regulated by Ron and DEK are not fully understood, both are known to activate Wnt/β-catenin signaling. Both also have been implicated in promoting the activity of other oncogenic signaling cascades linked to cancer progression, including the roles of DEK in regulating the function of p53 family members and DNA repair, and of Ron in promoting the activation of PI3K-Akt and Ras/MAPK pathways. 13, 29, 52, 69 Combined, we propose that Ron and DEK cooperate to drive breast cancer progression and relapse. Developing novel therapeutics that target these proteins could significantly slow tumor growth and limit the risk of metastasis or disease relapse, and may be particularly effective when combined with traditional therapies.
MATERIALS AND METHODS

Cell culture
T47D and MCF10A cells were obtained from the American Type Culture Collection and grown under recommended conditions. R7 cells are a murine mammary tumor line from a previously described MMTV-Ron mouse. 3, 39 We established the remaining cell lines from mammary tumors that developed in the MMTV-Ron (Ron tg ) mice used in this study. Cell lines R7, RD258 and RD272 were generated from Ron tg Dek +/+ tumors and cell lines RD147, RD219, RD238 and RD271 were from Ron tg Dek − / − tumors. Briefly, tumor fragments were digested in 2 mg/ml collagenase in DMEM: F12 media for 2 h at 37°C and then washed six times in phosphatebuffered saline with differential centrifugation to enrich for epithelial cells. Resulting organoids were grown in DMEM:F12 media supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin, 1% Fungizone, 2 mM L-glutamine, 5 μg/ml gentamicin, 10 ng/ml epidermal growth factor, 10 μg/ml human recombinant insulin, 5 μg/ml transferrin and 50 μM sodium selenite and then passaged at least 20 times.
Cells were treated with 100 ng/ml recombinant HGFL protein (MSP, Cys 672 Ala; R&D Systems, Minneapolis, MN, USA) for the indicated time points. To inhibit Wnt secretion, cells were treated with 10 μM IWP-2 (SigmaAldrich, St Louis, MO, USA) for 24 h before analysis. For growth curves, cells were plated at equal density of 50 000 cells per well in 6-well plates, trypsinized and counted in triplicate using a hemocytometer.
3D MCF10A cultures were generated and stained by immunofluorescence as described previously. 46 MCF10A cells retrovirally transduced with R780 and R780:DEK also were described previously. 29 Acinar structures were photographed at day 4 for invasive cultures (Matrigel and collagen) at ×100 total magnification. Immunofluorescence was performed on day 20 of culture and visualized with a Zeiss LSM510 scanning confocal microscope (Carl Zeiss Microscopy GmbH, Jena, Germany).
Cells were transduced with retroviral constructs, R780 and R780:mDek containing an mDek construct, as described previously and sorted based were grown in Matrigel 3D culture (top and middle panels) to test for morphology or Matrigel-collagen 3D cultures to test for invasion (bottom panel). Immunofluorescence was performed on day 20 of culture and visualized with a Zeiss LSM510 scanning confocal microscope; the white size bar represents 10 μm. Phase-contrast images are also shown in the middle and bottom panels, and black arrows indicate invading cells in the bottom panel. The Golgi marker GM130 is used to mark cell apical-basal polarity, and white arrows highlight cells with deregulated polarity. The percentage of cells with mislocalized GM130 per acinar structure is depicted below the images, which was calculated from triplicate experiments. (d) DEK and Ron expression predict β-catenin expression levels in primary human breast cancer. Serial sections from two tissue microarrays of patient-derived breast infiltrating ductal carcinomas were stained by immunohistochemistry for Dek, Ron and β-catenin expression. Correlation was analyzed by χ 2 testing. (e and f) Combined DEK and Ron expression predict disease relapse in a cohort of 1000 unmedicated patients (P = 0.00018) (e) and progression to distant metastatic disease in 1609 patients treated with systemic therapies (P = 0.00098) (f). A meta-analysis of patient and gene expression data archived in Kaplan-Meier Plotter (http://www.kmplot.com) was performed to generate Kaplan-Meier curves. The numbers under each graph represent the number of patients at each time point.
on GFP expression 30 or transduced with the lentiviral pLKO.1 constructs (Deksh represents pLKO.1_DEK832 in the Mission library (Sigma-Aldrich) and was previously described as 'DEKsh2'
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) and selected in 4 μg/ml puromycin. NTsh is a non-targeting control. All cell populations were analyzed within six passages of selection.
PCR
Total mRNA was isolated using Trizol extraction, and then reverse transcribed using the Quantitect kit (Qiagen, Valencia, CA, USA). cDNA was amplified with SYBR Green PCR master mix using an ABI-7500 quantitative PCR machine (Applied Biosystems, Carlsbad, CA, USA) and analyzed using the ΔΔCt method. The following forward (F) and reverse (R) primer pairs were used at a concentration of 0.4 ng/μl each (primers labeled with 'm' were used for murine cells and those with an 'h' denote human sequence): mDek F (5′-AACGTGGGTCAGTTCAGTGGC-3′); mDek R (5′-TTCGCTGTTCACGCCTGACCT-3′); mActin F (5′-GATATCGCTGCGCTGGTC GTC-3′); mActin R (5′-ACCATCACACCCTGGTGCCTAG-3′); mWnt4 F (5′-AGC AGGTGTGGCCTTTGCAGTGAC-3′); mWnt4 R (5′-CGTTGTTGTGAAGATTCATG AGTGCC-3′); mWnt7b F (5′-AGTGGATCTTTTACGTGTTTCTCTG-3′); mWnt7b R (5′-CTGGTTGTAGTAGCCTTGCTTCTC-3′); mWnt10b F (5′-AGAAGTTCTC TCGGGATTTCTTG-3′); mWnt10b R (5′-CAAAGTAAACCAGCTCTCCAG-3′); hGAPDH F (5′-GGTCTCCTCTGACTTCAACA-3′); hGAPDH R (5-ATACCAGGAA ATGAGCTTGA-3′); hDEK F (5′-TGTTAAGAAAGCAGATAGCAGCACC-3′); hDEK R (5′-ATTAAAGGTTCATCATCTGAACTATCCTC-3′).
Western blotting
Total protein was extracted with RIPA buffer and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis before being transferred to a PVDF membrane. Blots were probed with specific antibodies to DEK (BD Bioscience, San Jose, CA, USA); Ron (C-20), Wnt10b (H70) and cyclin D1 (72-13G) (Santa Cruz, Dallas, TX, USA); α-tubulin (Sigma Aldrich), actin C4 (gift from James Lessard, Cincinnati Children's Hospital, Cincinnati, OH, USA); axin 2, MMP2 and MMP9 (Abcam, Cambridge, MA, USA), cytokeratin 14 (Covance, Princeton, NJ, USA) and GSK3β, phospho-ERK1/2, total ERK1/2 and TCF1 (Cell Signaling, Danvers, MA, USA). Protein from primary MECs was collected from 18-week-old nulliparous, nontumor-bearing Dek +/+ females by isolating the cells through collagenase digestion and differential centrifugation as described above immediately before the addition of lysis buffer. For secreted proteins, 3 × 10 6 cells were plated on 10 cm dishes in complete media for 2 h and then cells were washed in phosphate-buffered saline and overlayed with media containing 1% FBS for 24 h. Six milliliters of conditioned media were collected from each cell line and concentrated to 100 μl using Amicon Ultra-4 centrifugal filters with Ultracel-3 membrane (Millipore, Billerica, MA, USA) and then 2 μl was diluted into 18 μl of serum-free media before western blotting. Western blots were analyzed by densitometry using Image J (National Institutes of Health, Washington, DC, USA). 70 71, 72 Two hours before being killed, the mice were intraperitoneally injected with 600 μg of BrdU. At necropsy, the mice were weighed and the tumors were excised, measured, weighed, fixed in 4% paraformaldehyde and embedded in paraffin. Portions of one tumor per mouse were used to generate novel Ron tg Dek +/+ and Ron tg Dek − / − cell lines (see above). Lungs and livers were examined for metastases as described previously. 73 For allograft tumor studies, 5 × 10 5 cells suspended in phosphatebuffered saline were injected into the inguinal mammary fat pads of nulliparous, 12-week-old female athymic nude mice. Tumors were measured and collected as described above. Usage and handling of mice was performed with the approval of the Cincinnati Children's Institutional Animal Care and Use Committee. All mice were housed in specific pathogen-free housing with ad libitum access to food and water.
Mice
Immunohistochemistry
Paraformaldehyde-fixed and paraffin-embedded tissues were cut into 5 μm sections, subjected to sodium citrate antigen retrieval and stained using the M.O.M. Peroxidase Kit (Vector Labs, Burlingame, CA, USA) and 3,3′-diaminobenzidine. The following antibodies were used: DEK (1:60; BD Biosciences), BrdU (1:100; Molecular Probes, Invitrogen, Grand Island, NY, USA), Wnt10b (H70) (1:50; Santa Cruz), MMP2 and MMP9 (1:100 and 1:200, respectively; Santa Cruz), cytokeratin 5 (1:200; Abcam) or activated β-catenin (8E7) (1:100; Millipore). Samples were counterstained with 0.1% Nuclear Fast Red (Poly Scientific, Bay Shore, NY, USA) and preserved with Permount (Fisher Scientific, Pittsburgh, PA, USA). Tissue microarrays were purchased from Imgenex (San Diego, CA, USA; CBA2 and CBB2) for correlations of Ron, DEK and β-catenin expression in human tissues and scored as described previously. 6 For tumors generated from R7 NTsh and Deksh cells, staining intensity was quantified by the Threshold tool on Image J. The threshold for each section was set and normalized to each section's respective total area of tissue as seen at × 200 total magnification. Scores were calculated by multiplying the intensity score by the percentage of positive staining cells. The total number of cells counted per section ranged from 122 to 357. For activated β-catenin staining, cells were considered positive if the nucleus showed 3,3′-diaminobenzidine staining.
Flow cytometry
All flow cytometry was performed on a FACSCanto cytometer (BD Biosciences). Mouse cell surface marker staining was determined with the Lineage Cocktail Kit and streptavidin-APC-Cy7 in combination with CD44-PE, CD49f-FITC and CD24-APC antibodies (all from BD Biosciences). For coculturing experiments, 2 × 10 5 cells of each genotype were plated in 60 mm dishes, grown overnight and then treated with 100 μM BrdU for 35 min before staining with the APC BrdU Kit (BD Biosciences). BrdU incorporation was measured in GFP − and GFP + cells.
Mammosphere culture
Mammosphere cultures were performed and photographed as described previously. 29 Image J was used to measure the radius and calculated sphere volume as (4/3)π × r 3 for each mammosphere in triplicate experiments.
Invasion assay
Matrigel transwell assays were used to determine invasive potential in vitro (BD Biosciences). Cells were seeded at low density in supplement-free media and complete media were placed into the bottom chamber as a chemoattractant. After 20 h, invading cells were methanol fixed and 
Kaplan-Meier curves
Kaplan-Meier plots were generated with KM plotter for Breast Cancer, 2014 version (http: //www.kmplot.com), which is a publicly available online database of archived gene expression and patient survival data. 74 We used the multigene classifier and mean expression of probes, 200934_at (DEK) and 205455_at (Ron), and did not restrict analysis by subtype. We analyzed relapse-free survival in systemically untreated patients and distant metastasis-free survival in patients treated with endocrine therapies or chemotherapies.
Statistics
Mouse tumor-free survival was analyzed using the log-rank test. The χ 2 test was used to identify correlations with protein expression using tissue microarrays. For all other experiments, an unpaired two-tailed Student's t-test was used, unless otherwise noted. Error bars depict standard error of data collected from at least three experiments. Significance was set at Po0.05. One asterisk (*) indicates Po 0.05, two asterisks (**) indicate Po0.01 and three asterisks (***) indicate Po0.001.
